[go: up one dir, main page]

MX2012006744A - Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. - Google Patents

Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.

Info

Publication number
MX2012006744A
MX2012006744A MX2012006744A MX2012006744A MX2012006744A MX 2012006744 A MX2012006744 A MX 2012006744A MX 2012006744 A MX2012006744 A MX 2012006744A MX 2012006744 A MX2012006744 A MX 2012006744A MX 2012006744 A MX2012006744 A MX 2012006744A
Authority
MX
Mexico
Prior art keywords
treatment
ppar
combinations
diabetes mellitus
metabolic diseases
Prior art date
Application number
MX2012006744A
Other languages
English (en)
Inventor
Scott D Larsen
Steven P Tanis
Rolf F Kletzien
Gerard R Colca
Original Assignee
Metabolic Solutions Dev Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co Llc filed Critical Metabolic Solutions Dev Co Llc
Publication of MX2012006744A publication Critical patent/MX2012006744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a análogos de tiazolidinadionas y composiciones farmacéuticas que son útiles para tratar y/o prevenir diabetes mellitus, opcionalmente en combinción con un segundo tratamientol. Adicionalmente, la presente invención también proporciona métodos para inducir la remisión de los síntomas de diabetes mellitus en un paciente que comprende en administrar un análogo de tiazolinidinadionas y un agonista de GLP-1.
MX2012006744A 2009-12-15 2010-12-15 Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. MX2012006744A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28673809P 2009-12-15 2009-12-15
US28676509P 2009-12-15 2009-12-15
US29674810P 2010-01-20 2010-01-20
PCT/US2010/060453 WO2011084456A1 (en) 2009-12-15 2010-12-15 Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases

Publications (1)

Publication Number Publication Date
MX2012006744A true MX2012006744A (es) 2012-07-30

Family

ID=43707800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006744A MX2012006744A (es) 2009-12-15 2010-12-15 Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.

Country Status (10)

Country Link
US (1) US20120322728A1 (es)
EP (1) EP2512471A1 (es)
JP (1) JP2013514369A (es)
KR (1) KR20120092712A (es)
CN (1) CN102753170A (es)
AU (1) AU2010340058A1 (es)
CA (1) CA2783264A1 (es)
MX (1) MX2012006744A (es)
RU (1) RU2012130011A (es)
WO (1) WO2011084456A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102029560B1 (ko) 2009-12-15 2019-10-07 씨리우스 테라퓨틱스, 엘엘씨 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211231A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
WO2019154958A1 (en) 2018-02-08 2019-08-15 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
US11931345B2 (en) * 2018-05-04 2024-03-19 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases
GB202303229D0 (en) * 2023-03-06 2023-04-19 Atrogi Ab New medical uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
EP2902026B1 (en) * 2006-03-16 2017-10-04 Metabolic Solutions Development Company LLC Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
MX2008011870A (es) * 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Terapias de combinacion de analogos de tiazolidindiona y agonistas glucocorticoides.
EP2203433B1 (en) * 2007-09-14 2012-10-31 Metabolic Solutions Development Company LLC 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues

Also Published As

Publication number Publication date
US20120322728A1 (en) 2012-12-20
CN102753170A (zh) 2012-10-24
EP2512471A1 (en) 2012-10-24
WO2011084456A1 (en) 2011-07-14
RU2012130011A (ru) 2014-01-27
JP2013514369A (ja) 2013-04-25
WO2011084456A9 (en) 2012-06-21
KR20120092712A (ko) 2012-08-21
CA2783264A1 (en) 2011-07-14
AU2010340058A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
AR081254A1 (es) Composicion farmaceutica que comprende ave0010 e insulina glargina
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
EA201590759A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
EA201190054A1 (ru) Аналоги глюкагона
EA201190047A1 (ru) Аналоги глюкагона
EA201190049A1 (ru) Аналоги глюкагона
EA201190048A1 (ru) Аналоги глюкагона
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
WO2008050329A3 (en) Novel sirnas and methods of use thereof
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
WO2008120813A1 (ja) ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
EA200870575A1 (ru) Композиции и способы лечения застойной сердечной недостаточности
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
WO2012125830A3 (en) Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
WO2008058274A3 (en) Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
MX2013013307A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal